Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles

References

• Seufferlein T, Bachet J, Van Cutsem E, Rougier P; ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO–ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl_7):vii33–vii40.22997452
   PubMedGoogle Scholar
• Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers. 2011;3(2):1513–1526. doi:10.3390/cancers302151324212772
   PubMedGoogle Scholar
• Vaccaro V, Melisi D, Bria E, et al. Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Expert Opin Ther Targets. 2011;15(10):1183–1196. doi:10.1517/14728222.2011.60743821819318
   PubMed Web of Science ®Google Scholar
• Gillen S, Schuster T, Zum Büschenfelde CM, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. doi:10.1371/journal.pmed.100026720422030
   PubMed Web of Science ®Google Scholar
• Giuliani F, Di Maio M, Colucci G, Perrone F. Conventional chemotherapy of advanced pancreatic cancer. Curr Drug Targets. 2012;13(6):795–801. doi:10.2174/13894501280056414922458526
   PubMedGoogle Scholar
• Moertel CG. Clinical management of advanced gastrointestinal cancer. Cancer. 1975;36(S2):675–682.168961
   PubMedGoogle Scholar
• Philip PA, Lutz MP. Targeting epidermal growth factor receptor–related signaling pathways in pancreatic cancer. Pancreas. 2015;44(7):1046–1052. doi:10.1097/MPA.000000000000038926355547
   PubMedGoogle Scholar
• Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. doi:10.1016/j.phrs.2013.11.00224269963
   PubMed Web of Science ®Google Scholar
• Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology. 2014;28(1):6–14.25387681
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi:10.1056/NEJMoa101192321561347
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa130436924131140
   PubMed Web of Science ®Google Scholar
• Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13(3):565–569.8317885
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–769. doi:10.1038/sj.clpt.610040017957183
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62(2):90–99. doi:10.1016/j.phrs.2010.03.00520380880
   PubMed Web of Science ®Google Scholar
• Haqq J, Howells LM, Garcea G, Metcalfe MS, Steward WP, Dennison AR. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. Eur J Cancer. 2014;50(15):2570–2582. doi:10.1016/j.ejca.2014.06.02125091797
   PubMedGoogle Scholar
• Apte MV, Wilson JS, Lugea A, Pandol SJ. A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology. 2013;144(6):1210–1219. doi:10.1053/j.gastro.2012.11.03723622130
   PubMed Web of Science ®Google Scholar
• Nedaeinia R, Avan A, Manian M, Salehi R, Ghayour-Mobarhan M. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies. Curr Drug Targets. 2014;15(14):1293–1301. doi:10.2174/138945011566614112512300325429712
   PubMed Web of Science ®Google Scholar
• Karandish F, Mallik S. Biomarkers and targeted therapy in pancreatic cancer. Biomark Cancer. 2016;8:27–35. doi:10.4137/BiC.s3441427147897
   PubMedGoogle Scholar
• Martin-Fernandez ML, Clarke DT, Roberts SK, Zanetti-Domingues LC, Gervasio FL. Structure and dynamics of the EGF receptor as revealed by experiments and simulations and its relevance to non-small cell lung cancer. Cells. 2019;8(4):316. doi:10.3390/cells8040316
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF–ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505. doi:10.1038/nrm196216829981
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Singh AP, Chakraborty S, et al. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 2008;68(7):2065–2070. doi:10.1158/0008-5472.CAN-07-604118381409
   PubMedGoogle Scholar
• Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):15–31. doi:10.1517/14728222.2011.64861722239438
   PubMed Web of Science ®Google Scholar
• Pereira NB, Do Carmo AC, Diniz MG, Gomez RS, Gomes DA, Gomes CC. Nuclear localization of epidermal growth factor receptor (EGFR) in ameloblastomas. Oncotarget. 2015;6(12):9679–9685. doi:10.18632/oncotarget.391925991665
   PubMedGoogle Scholar
• De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008;214(3):559–567. doi:10.1002/jcp.2126017894407
   PubMed Web of Science ®Google Scholar
• Ardito CM, Grüner BM, Takeuchi KK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 2012;22(3):304–317. doi:10.1016/j.ccr.2012.07.02422975374
   PubMed Web of Science ®Google Scholar
• Cook N, Frese KK, Moore M. Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. Gastrointest Cancer Targets Ther. 2014;4:23–37.
   Google Scholar
• Hackeng WM, Hruban RH, Offerhaus GJA, Brosens LA. Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol. 2016;11(1):47. doi:10.1186/s13000-016-0497-z27267993
   PubMedGoogle Scholar
• Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol. 1991;163((2):):111–116. doi:10.1002/path.17116302061707959
   PubMedGoogle Scholar
• Tzeng CD, Frolov A, Frolova N, et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007;141(4):464–469. doi:10.1016/j.surg.2006.09.00917383523
   PubMed Web of Science ®Google Scholar
• Valsecchi ME, McDonald M, Brody JR, et al. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118(14):3484–3493. doi:10.1002/cncr.2666122086503
   PubMedGoogle Scholar
• Faloppi L, Andrikou K, Cascinu S. Cetuximab: still an option in the treatment of pancreatic cancer? Expert Opin Biol Ther. 2013;13(5):791–801. doi:10.1517/14712598.2013.78669723560505
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–1966. doi:10.1200/JCO.2006.07.952517452677
   PubMed Web of Science ®Google Scholar
• Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP. 2007;8(1):4–15.17228128
   PubMedGoogle Scholar
• Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine. 2013;8(9):1509–1528. doi:10.2217/nnm.13.11823914966
   PubMed Web of Science ®Google Scholar
• Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-Purification of Receptor and Epidermal Growth Factor-Enhanced Phosphorylation Activity. J Biol Chem. 1980;255(10):4834–4842.6246084
   PubMed Web of Science ®Google Scholar
• Conte A, Sigismund S. Chapter six-the ubiquitin network in the control of EGFR endocytosis and signaling In: Teplow DB, editor. Progress in Molecular Biology and Translational Science. Vol. 141 Elsevier; 2016:225–276.
   Google Scholar
• Edwin F, Wiepz GJ, Singh R, Peet CR, Chaturvedi D, Patel TB. A historical perspective of the EGF receptor and related systems. In: Patel TB, Bertics PJ, editors. Epidermal Growth Factor. Springer; 2006:1–24.
   Google Scholar
• Roepstorff K, Grandal MV, Henriksen L, et al. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic. 2009;10(8):1115–1127. doi:10.1111/j.1600-0854.2009.00943.x19531065
   PubMed Web of Science ®Google Scholar
• Siwak DR, Carey M, Hennessy BT, et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol. 2010;2010:568938. doi:10.1155/2010/56893820037743
   PubMedGoogle Scholar
• Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16(10):5276–5287. doi:10.1128/mcb.16.10.52768816440
   PubMed Web of Science ®Google Scholar
• Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9(5):52.
   PubMed Web of Science ®Google Scholar
• Hu CD, Kariya K, Tamada M, et al. Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras. J Biol Chem. 1995;270(51):30274–30277. doi:10.1074/jbc.270.51.302748530446
   PubMed Web of Science ®Google Scholar
• Roy S, Lane A, Yan J, McPherson R, Hancock JF. Activity of plasma membrane-recruited Raf-1 is regulated by Ras via the Raf zinc finger. J Biol Chem. 1997;272(32):20139–20145. doi:10.1074/jbc.272.32.201399242688
   PubMedGoogle Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291. doi:10.1038/sj.onc.121042217496923
   PubMed Web of Science ®Google Scholar
• Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 2015;25(9):545–555. doi:10.1016/j.tcb.2015.06.00226159692
   PubMed Web of Science ®Google Scholar
• Bjorge JD, Chan TO, Antczak M, Kung HJ, Fujita DJ. Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. Proc Natl Acad Sci U S A. 1990;87(10):3816–3820. doi:10.1073/pnas.87.10.38162160078
   PubMedGoogle Scholar
• Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996;93(8):3636–3641. doi:10.1073/pnas.93.8.36368622988
   PubMed Web of Science ®Google Scholar
• Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873–886. doi:10.1016/j.cell.2009.03.04619446321
   PubMed Web of Science ®Google Scholar
• Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010;62(3):346–361. doi:10.1016/j.addr.2009.11.00719914317
   PubMed Web of Science ®Google Scholar
• Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2012;64::353–365. doi:10.1016/j.addr.2012.09.01124511174
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2012;64:24–36. doi:10.1016/j.addr.2012.09.006
   Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615–1626. doi:10.1016/j.addr.2008.08.00518840489
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310–1316. doi:10.1158/1078-0432.CCR-07-144118316549
   PubMed Web of Science ®Google Scholar
• Martinelli C, Pucci C, Ciofani G. Nanostructured carriers as innovative tools for cancer diagnosis and therapy. APL Bioeng. 2019;3(1):011502. doi:10.1063/1.507994331069332
   PubMed Web of Science ®Google Scholar
• Mout R, Moyano DF, Rana S, Rotello VM. Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev. 2012;41(7):2539–2544. doi:10.1039/c2cs15294k22310807
   PubMed Web of Science ®Google Scholar
• Ma N, Ma C, Li C, et al. Influence of nanoparticle shape, size, and surface functionalization on cellular uptake. J Nanosci Nanotechnol. 2013;13(10):6485–6498. doi:10.1166/jnn.2013.752524245105
   PubMed Web of Science ®Google Scholar
• Lu HS, Chai JJ, Li M, Huang BR, He CH, Bi RC. Crystal structure of human epidermal growth factor and its dimerization. J Biol Chem. 2001;276(37):34913–34917. doi:10.1074/jbc.M10287420011438527
   PubMed Web of Science ®Google Scholar
• Master AM, Sen Gupta A. EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine. 2012;7(12):1895–1906. doi:10.2217/nnm.12.16023249333
   PubMed Web of Science ®Google Scholar
• Bhirde AA, Patel V, Gavard J, et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano. 2009;3(2):307–316. doi:10.1021/nn800551s19236065
   PubMed Web of Science ®Google Scholar
• Tseng C, Wu SY, Wang W, et al. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials. 2008;29(20):3014–3022. doi:10.1016/j.biomaterials.2008.03.03318436301
   PubMed Web of Science ®Google Scholar
• Shimada T, Ueda M, Jinno H, et al. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res. 2009;29(4):1009–1014.19414339
   PubMed Web of Science ®Google Scholar
• Sandoval MA, Sloat BR, Lansakara-P DS, et al. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J Control Release. 2012;157(2):287–296. doi:10.1016/j.jconrel.2011.08.01521871505
   PubMed Web of Science ®Google Scholar
• Song L, Falzone N, Vallis KA. EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer. Int J Radiat Biol. 2016;92(11):716–723. doi:10.3109/09553002.2016.114536026999580
   PubMed Web of Science ®Google Scholar
• Shevtsov MA, Nikolaev BP, Yakovleva LY, et al. Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors. Int J Nanomedicine. 2014;9:273–287. doi:10.2147/IJN.S5511824421639
   PubMed Web of Science ®Google Scholar
• Creixell M, Herrera AP, Ayala V, et al. Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells. J Magn Magn Mater. 2010;322(15):2244–2250. doi:10.1016/j.jmmm.2010.02.019
   Web of Science ®Google Scholar
• Le UM, Hartman A, Pillai G. Enhanced selective cellular uptake and cytotoxicity of epidermal growth factor-conjugated liposomes containing curcumin on EGFR-overexpressed pancreatic cancer cells. J Drug Target. 2018;26(8):676–683. doi:10.1080/1061186X.2017.140811429157028
   PubMed Web of Science ®Google Scholar
• Kim W, Na K, Lee K, Lee HW, Lee JK, Kim K. Selective uptake of epidermal growth factor-conjugated gold nanoparticle (EGF-GNP) facilitates non-thermal plasma (NTP)-mediated cell death. Sci Rep. 2017;7(1):10971. doi:10.1038/s41598-017-11292-z28887524
   PubMed Web of Science ®Google Scholar
• Silva CO, Petersen SB, Reis CP, et al. EGF functionalized polymer-coated gold nanoparticles promote EGF photostability and EGFR internalization for photothermal therapy. PLoS One. 2016;11(10):e0165419. doi:10.1371/journal.pone.016541927788212
   PubMedGoogle Scholar
• Karmakar A, Iancu C, Bartos DM, et al. Raman spectroscopy as a detection and analysis tool for in vitro specific targeting of pancreatic cancer cells by EGF‐conjugated, single‐walled carbon nanotubes. J Appl Toxicol. 2012;32(5):365–375. doi:10.1002/jat.v32.522147491
   PubMedGoogle Scholar
• Wu L, Yu X, Feizpour A, Reinhard BM. Nanoconjugation: a materials approach to enhance epidermal growth factor induced apoptosis. Biomater Sci. 2014;2(2):156–166. doi:10.1039/C3BM60142K24683470
   PubMed Web of Science ®Google Scholar
• Pan Y, Leifert A, Ruau D, et al. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. Small. 2009;5(18):2067–2076. doi:10.1002/smll.v5:1819642089
   PubMed Web of Science ®Google Scholar
• Khanehzar A, Fraire JC, Xi M, et al. Nanoparticle–cell interactions induced apoptosis: a case study with nanoconjugated epidermal growth factor. Nanoscale. 2018;10(14):6712–6723. doi:10.1039/C8NR01106K29589623
   PubMed Web of Science ®Google Scholar
• Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2009;315(4):683–696. doi:10.1016/j.yexcr.2008.07.02919278030
   PubMed Web of Science ®Google Scholar
• Rush JS, Quinalty LM, Engelman L, Sherry DM, Ceresa BP. Endosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosis. J Biol Chem. 2012;287(1):712–722. doi:10.1074/jbc.M111.29447022102283
   PubMedGoogle Scholar
• Wu L, Xu F, Reinhard B. Nanoconjugation prolongs endosomal signaling of the epidermal growth factor receptor and enhances apoptosis. Nanoscale. 2016;8(28):13755–13768. doi:10.1039/C6NR02974D27378391
   PubMed Web of Science ®Google Scholar
• Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. Nanotechnologies in pancreatic cancer therapy. Pharmaceutics. 2017;9(4):39. doi:10.3390/pharmaceutics9040039
   PubMed Web of Science ®Google Scholar
• Wang L, Liu X, Zhou Q, et al. Terminating the criminal collaboration in pancreatic cancer: nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Biomaterials. 2017;144:105–118. doi:10.1016/j.biomaterials.2017.08.00228837958
   PubMed Web of Science ®Google Scholar
• Arachchige MP, Laha SS, Naik AR, Lewis KT, Naik R, Jena BP. Functionalized nanoparticles enable tracking the rapid entry and release of doxorubicin in human pancreatic cancer cells. Micron. 2017;92:25–31. doi:10.1016/j.micron.2016.10.00527846432
   PubMedGoogle Scholar
• Emamzadeh M, Desmaële D, Couvreur P, Pasparakis G. Dual controlled delivery of squalenoyl-gemcitabine and paclitaxel using thermo-responsive polymeric micelles for pancreatic cancer. J Mater Chem B. 2018;6(15):2230–2239. doi:10.1039/C7TB02899G
   PubMed Web of Science ®Google Scholar
• Malekigorji M, Alfahad M, Lin PKT, Jones S, Curtis A, Hoskins C. Thermally triggered theranostics for pancreatic cancer therapy. Nanoscale. 2017;9(34):12735–12745. doi:10.1039/C7NR02751F28829476
   PubMedGoogle Scholar
• Oluwasanmi A, Al-Shakarchi W, Manzur A, et al. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. J Control Release. 2017;266:355–364.28943195
   PubMed Web of Science ®Google Scholar
• Liu X, Situ A, Kang Y, et al. Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer. ACS Nano. 2016;10(2):2702–2715. doi:10.1021/acsnano.5b0778126835979
   PubMed Web of Science ®Google Scholar